PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024 - New Report Available

From: Fast Market Research, Inc.
Published: Fri Jul 22 2016

Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Although not life-threatening, Psoriasis causes tremendous morbidity and personal angst for patients.

GlobalData projects the psoriasis market in 8MM to experience modest growth during the forecast period at a CAGR of 7.26%. This growth will be driven primarily by the highly anticipated arrivals of promising systemic therapies- interleukin-23 (IL-23) inhibitors (guselkumab and tildrakizumab), interleukin-17 (IL-17) inhibitors (Cosentyx, Taltz, and brodalumab) as well as phsophodiesterase (PDE4) inhibitor- Otezla (apremilast). Nevertheless, looming patent expiries of high-grossing branded drugs- especially TNF inhibitors, Humira, Enbrel and Remicade, in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with rapid global developments of biosimilars , are expected to spread the growth throughout the different classes of products, away from the branded TNF inhibitors which have traditionally been the main driver of growth in the prior years.

Full Report Details at


Key Questions Answered

* How good is the management of Psoriasis with marketed therapies?
* Which drugs and players are important in the current management landscape?
* What are the most promising late-stage pipeline drugs and how will their launch shape the future treatment landscape in the Psoriasis market?
* What are the significant unmet needs and remaining opportunities in the Psoriasis market?
* What clinical and commercial factors are likely to uptake of Psoriasis therapies in the US, 5EU, Japan and India?

Key Findings

* The psoriasis market is currently very dynamic, with effective biologic therapies awaiting approval, such as interleukin-17 (IL-17) inhibitor- brodalumab, interleukin-23 (IL-23) inhibitors- guselkumab and tildrakizumab.
* Novel biologic therapies will challenge the current anti-TNF biologics in an attempt to dislodge their stronghold, if their safety and efficacy profiles are proven once they enter the market.
* The impending patent cliff for biologics will allow for the emergence of biosimilars to all the marketed biologic brands. Patent expiries take place during the forecast period for the current market leaders such as Johnson & Johnson's Remicade (infliximab), AbbVie's Humira (adalimumab), Amgen's Enbrel (etanercept) and Johnson & Johnson's Stelara (ustekinumab).
* The drivers for market growth will also include affordable treatments throughout the world, as well as the push for long-term drug efficacy. The main challenge for individual drugs will be to distinguish themselves in a crowded marketplace, comprising a highly diversified field of therapies, with existing drugs struggling to increase their patient share.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- PharmaPoint: Hemophilia A and B Recombinant Factor Replacement Therapy - Global Drug Forecast and Market Analysis to 2024
- PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024
- PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024
- Psoriasis - 5EU Drug Forecast and Market Analysis to 2024
- Psoriasis - Japan Drug Forecast and Market Analysis to 2024

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »